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DNA methylation and DNA 
methyltransferases
John R. Edwards1, Olya Yarychkivska2, Mathieu Boulard2 and Timothy H. Bestor2* 
Abstract 
The prevailing views as to the form, function, and regulation of genomic methylation patterns have their origin many 
years in the past, at a time when the structure of the mammalian genome was only dimly perceived, when the num-
ber of protein-encoding mammalian genes was believed to be at least five times greater than the actual number, and 
when it was not understood that only ~10% of the genome is under selective pressure and likely to have biological 
function. We use more recent findings from genome biology and whole-genome methylation profiling to provide a 
reappraisal of the shape of genomic methylation patterns and the nature of the changes that they undergo during 
gametogenesis and early development. We observe that the sequences that undergo deep changes in methylation 
status during early development are largely sequences without regulatory function. We also discuss recent findings 
that begin to explain the remarkable fidelity of maintenance methylation. Rather than a general overview of DNA 
methylation in mammals (which has been the subject of many reviews), we present a new analysis of the distribu-
tion of methylated CpG dinucleotides across the multiple sequence compartments that make up the mammalian 
genome, and we offer an updated interpretation of the nature of the changes in methylation patterns that occur in 
germ cells and early embryos. We discuss the cues that might designate specific sequences for demethylation or de 
novo methylation during development, and we summarize recent findings on mechanisms that maintain methyla-
tion patterns in mammalian genomes. We also describe the several human disorders, each very different from the 
other, that are caused by mutations in DNA methyltransferase genes.
Keywords: Epigenetics, DNA cytosine methylation, Mammalian DNA methyltransferases, Methylation dynamics, 
Methylation-related human diseases
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
The shape of genomic methylation patterns
The current human genome assembly contains ~3 × 107 
CpG dinucleotides, each of which can exist in the methyl-
ated or unmethylated state. The number of possible meth-
ylation patterns in a single haploid genome far exceeds the 
number of atoms in the observable universe; this greatly 
increases both the potential information content of the 
genome and the difficulty of statistical analysis [1, 2].
Whole-genome methylation profiling has recently 
made it possible to assign approximate methylation lev-
els to the multiple sequence compartments that make 
up the human genome [1–3]. We have analyzed this 
compartment-specific methylation as it occurs in dif-
ferentiated somatic cells; the data are shown in Fig.  1. 
Transposon-derived sequences (SINE, LINE, and LTR) 
are abundant and densely methylated; the remainder of 
the genome is more variably methylated, with promoter-
associated CpG islands and first exons representing the 
only sequence compartment that is largely unmethylated. 
Seventy-five percent of all promoters are within CpG 
islands and unmethylated [1–4]; the remaining promot-
ers have very low CpG densities, and methylation is very 
unlikely to regulate their expression [1, 2]. Many CpG 
islands are not associated with promoters or other anno-
tated regulatory sequences, and their methylation status 
is of unknown and possibly inconsequential  biological 
significance.
Current evidence indicates that the primary biologi-
cal functions of DNA methylation lie in the heritable 
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transcriptional repression of retrotransposons, the mon-
oallelic expression of imprinted genes, X chromosome 
inactivation in female cells, and the selective exposure of 
promoters of cellular genes to transcription factors. There 
is evidence that genomic methylation patterns at regula-
tory sequences are essentially static during development, 
although CpG-poor promoters can show partial demeth-
ylation upon transcriptional activation that is likely to be a 
consequence rather than a cause of activation [2].
Multiple lines of evidence indicate that only ~10% 
of the mammalian genome is functional, as shown by 
comparative biology studies and by the fact that most of 
the genome is evolving at the neutral rate and does not 
appear to be under selection [6, 7]. Most DNA meth-
ylation is also likely to be without significant biological 
function; this is consistent with high rate of loss of CpG 
dinucleotides across most of the genome during evolu-
tion [8] and the highly heterogeneous nature of genomic 
methylation patterns even in single tissue types [1, 3].
Methylation dynamics during development
Since 1987, it has been held that there are two waves of 
demethylation and remethylation [9] during develop-
ment that in the standard depictions are implied to affect 
virtually the entire genome (reviewed in [10]). Under this 
model, the first wave of demethylation occurs during the 
migration of proliferating primordial germ cells, with 
remethylation occurring in postmigratory germ cells; 
the second wave of demethylation takes place in cleav-
age stage embryos and results in a minimum in DNA 
methylation at the blastocyst stage. As shown in Fig.  2, 
this standard double-dip model obscures the methyla-
tion dynamics of the small fraction of the genome shown 
in Fig.  1 where methylation is likely to exert regulatory 
effects. First, the large majority of CpG island promot-
ers are not subject to these waves of methylation and 
demethylation because they are unmethylated at all 
stages. Second, the methylation status of alleles at dif-
ferentially methylated regions (DMRs) of imprinting 
control regions (ICRs) changes at different developmen-
tal stages: they are demethylated in primordial germ 
cells and remethylated in cohorts of growing oocytes 
shortly before ovulation [11] and in the entire popula-
tion of prospermatogonia around the time of birth [12]. 
The sex-specific methylation at ICRs/DMRs escapes the 
demethylation that occurs in cleavage stage embryos. 
Third, the small population of young, CpG-rich trans-
posons largely escapes demethylation both in primordial 
germ cells [13] and in the early embryo [14]. The types 
of sequences that undergo the double wave of demeth-
ylation and remethylation are largely composed of old 
and inactive transposon remnants, satellite and other 
repeated DNA, and the unannotated and rapidly diverg-
ing fraction of the genome that shows little evidence of 
biological function. Figure 2 shows that the dynamics of 
demethylation and remethylation during development 
are more complex than depicted in the double-dip model 
and that sequences whose methylation status is of biolog-
ical importance do not conform to this model. 
Figure 2 also shows the basis for the pronounced sex-
ual dimorphism in the rate of C → T mutations driven 
by deamination of 5 methylcytosine  (m5C), which con-
verts the base directly to T. De novo methylation of 
DMRs/ICRs and most of the genome occurs in the 
entire population of male germ cells around the time 
of birth; these methylation patterns exist for the repro-
ductive life of the organism and must be propagated by 
maintenance methylation in spermatogonia through 
many mitotic divisions prior to entry into meiosis [12]. 
In female germ cells, de novo methylation takes place 
in growing oocytes, which are arrested in meiosis I and 
undergo no mitotic divisions prior to fertilization [11]; 
there is therefore very little opportunity for deamination 
of  m5C to occur. As a result of this sexual dimorphism, 
de novo mutations at CpG dinucleotides are much more 
common in spermatozoa [15]; many sporadic genetic 
disorders are caused primarily by C →  T mutations at 
methylated CpG dinucleotides at alleles of paternal 
Fig. 1 Distribution of DNA methylation across sequence compart-
ments in the human genome. Vertical axis indicates percentage of 
total CpG dinucleotides in each indicated compartment; horizontal 
axis indicates percentage of total genome in each compartment; light 
blue at the top of each compartment indicates unmethylated fraction. 
Numerals in red denote CpG dinucleotides per 100 bp. The genome-
wide CpG density expected on the basis of G + C content is 4.2 per 
100 bp. Note that the only sequence compartment that exists in the 
largely unmethylated state is the CpG island/first exon compartment; 
this compartment occupies <0.5% of the genome. The ICR/DMR 
compartment (differentially methylated regions of imprinting control 
regions) represents ~0.001% of the genome and ~0.01% of total CpG 
dinucleotides. Introns are included in the unannotated compartment, 
as are putative enhancers. The methylation data are from Bisulfite-Seq 
data for hippocampus (Roadmap Epigenome Project sample E071 
[5]), but other differentiated adult tissues show very similar trends
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origin. Furthermore, paternally methylated ICRs/DMRs 
have been eroded by C → T mutations over evolution-
ary time and are far fewer in number and have become 
reduced in CpG density as compared to maternally 
methylated ICRs/DMRs [16].
Attracting and repelling DNA methylation
The cues that designate specific sequences for de novo 
methylation, faithful versus error-prone maintenance 
methylation, or demethylation at different develop-
mental stages are not well understood. It is clear that 
the default state of most of the genome is partially to 
densely methylated [1, 3]. This is shown by the fact that 
removal of most DNA methylation in somatic cells by 
treatment with DNA methyltransferase inhibitors is fol-
lowed by gradual remethylation of most sequences after 
withdrawal of the inhibitor [17]; this methylation occurs 
largely at sequences that are unlikely to have appreciable 
biological effects. Restoration of DNMT1 to Dnmt1-null 
ES cells, whose genomes have lost nearly all  m5C, also 
results in the remethylation of most of the genome, but 
with a failure to reestablish methylation at imprinting 
control regions until these sequences have been passed 
through the germ line [18].
Fig. 2 Dynamics of demethylation and de novo methylation in the maternal (a) and paternal (b) genomes during mammalian development. The 
standard depictions of developmental changes in genomic methylation patterns often assume a monolithic genome; in fact, different sequence 
compartments display marked differences in timing of methylation and demethylation. CpG-rich (CpG island) promoters are unmethylated at all 
stages, except for the small number of CpG islands associated with imprinting control regions and CpG islands on the inactive X chromosome 
in somatic cells of females. Young, CpG-rich transposons largely escape both waves of demethylation. Most of the dynamic methylation and 
demethylation that occurs in primordial germ cells (PGCs) and the early embryo affects sequences that are evolving at the neutral rate and whose 
methylation status is without known biological effect. The methylation status of these sequences, which represent the bulk of the genome and are 
composed of satellite DNA, old and inactive transposons, introns, and unannotated sequences evolving at the neutral rate, is shown by broken lines
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Repeated sequences can attract de novo methylation; 
a transgene array of tandem repeats became methyl-
ated in transgenic mice, but methylation was lost when 
the repeat array was reduced to a single unit [19]. Other 
mechanisms by which repeated sequences might be 
targeted for de novo methylation have been discussed 
[20], although the actual mechanism by which repeated 
sequences attract de novo methylation has not been 
defined.
The mechanisms that designate specific sequences for 
de novo methylation in the germ line are only partially 
understood. Deletion of the gene that encodes DNMT3L 
(which is related to DNMT3A and DNMT3B in frame-
work regions but lacks the domains involved in trans-
methylation) causes a failure of de novo methylation in 
prospermatogonia [12] and in growing oocytes [11], the 
only cell types in which DNMT3L is expressed. DNMT3L 
forms a complex with DNMT3A and DNMT3B, and 
DNMT3L targets this complex to DNA sequences asso-
ciated with histones that are unmethylated at lysine 4 of 
histone H3 (H3K4); unmethylated H3K4 is associated 
with inactive promoters and with methylated DNA [21]. 
Ablation of the Argonaute proteins MILI or MIWI2, 
which are expressed in early germ cells and are involved 
in the biogenesis of PIWI-interacting RNAs (piRNAs), 
causes a failure of de novo methylation very similar to 
that seen in Dnmt3L-null germ cells, although DNA 
methylation is affected only in male germ cells [22]. This 
finding implies that piRNAs are upstream of histone 
H3K4 methylation and demethylation, which in turn are 
upstream of the DNMT3L/DNMT3A/DNMT3B com-
plex. However, it is not known how piRNAs affect H3K4 
methylation and no connection between piRNAs and the 
DNMT3L/DNMT3A/DNMT3B complex has been iden-
tified. DNMT3A and DNMT3B have also been shown to 
bind to H3K36me3 through their PWWP domains [23].
The binding of transcription factors to promoters 
even in the absence of active transcription can cause 
the loss of DNA methylation in the vicinity of the bind-
ing site [24]; even the binding of lac repressor can cause 
the loss of DNA methylation from CpG sites near lac 
operators in transfected mammalian cells [25]. Many of 
the expression–methylation correlations that have been 
reported since 1978 [26] are likely to be a consequence of 
transcriptional activation rather than a cause [2]. These 
effects are largely restricted to sequences of low CpG 
density. The expression of the large majority of genes 
does not markedly change after global genome demeth-
ylation [2].
CpG island promoters are protected from de novo 
methylation at essentially all developmental stages. 
Exceptions are a small number of promoters at ICR/
DMRs [27] and CpG island promoters on the inactive 
X chromosome in female somatic cells [28]. The mech-
anism that protects CpG island promoters does not 
involve sequestration of the promoters in condensed 
chromatin since unmethylated CpG-rich sequences in 
nuclei show the greatest accessibility to diffusible factors 
such as DNase I [1].
Although the mechanisms that protect most CpG 
island promoters from de novo methylation are not 
understood, a specific class of CpG island promoters is 
protected from de novo methylation by the multidomain 
chromosomal protein FBXL10 (also known as KDM2B, 
JHDM1B, and CXXC2); these are the CpG island pro-
moters bound by polycomb repressive complexes (PRC) 
1 and 2. In the absence of FBXL10, PRC-bound pro-
moters undergo de novo methylation with concomitant 
silencing of gene expression [29]. Even though FBXL10 is 
bound to essentially all CpG island promoters, removal 
of FBXL10 induces de novo methylation and transcrip-
tional silencing only of that small subset of CpG island 
promoters that are bound both by FBXL10 and by PRC 1 
and 2. This implies that PRC 1 and/or 2 has a tendency to 
attract de novo methylation and that FBXL10 has evolved 
to counteract this activity. Inhibition of de novo methyla-
tion is likely to involve the CXXC domain of FBXL10; this 
domain, which is found in ~14 nuclear proteins, binds 
specifically to unmethylated CpG dinucleotides [30]. The 
methylation abnormalities that arise in cells that lack 
FBXL10 are strikingly similar to those seen in pediatric 
ependymomas and some other pediatric cancers; the 
methylation abnormalities appear to be important driv-
ers of tumorigenesis as very few mutations have been 
detected in these tumors [31]. The processes that render 
PRC-bound promoters subject to de novo methylation in 
these tumors are not currently understood.
Mechanisms that mediate faithful maintenance 
methylation by DNMT1
That genomic methylation patterns are subject to mitotic 
inheritance in somatic cells was predicted to occur in 
1975 [32, 33] and demonstrated experimentally in 1981 
[34]. Maintenance methylation can be very faithful; 
allele-specific methylation patterns established at ICRs/
DMRs in germ cells of the preceding generation can be 
maintained in offspring through to adulthood with little 
alteration, and the two X chromosomes in female cells 
maintain different methylation patterns from soon after 
implantation of the embryo to the end of life.
However, maintenance methylation is less efficient at 
other sequences; methylation patterns can be heteroge-
neous in single tissue types [1, 3] and even in clonal cell 
populations. Heterogeneous methylation is observed 
largely at sequences without discernable regulatory 
activity. DNMT1 has long been known to preferentially 
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methylate hemimethylated DNA (the product of semi-
conservative DNA replication; reviewed in [35]), but 
only recently have structural studies begun to reveal the 
mechanism.
As shown in Fig.  3, DNMT1 has a C-terminal cata-
lytic domain related in sequence and structure to other 
DNA (cytosine-5) methyltransferases (including bacte-
rial restriction methyltransferases such as M.HhaI) and a 
large N-terminal region that contains multiple functional 
domains. The CXXC domain (which is closely related 
to that of FBXL10) binds to unmethylated CpG dinu-
cleotides and interposes a stretch of highly acidic amino 
acids (the autoinhibitory BAH1-CXXC linker in Fig.  3c 
and d) between the DNA and the active site of DNMT1, 
thereby inhibiting de novo methylation [30]. This auto-
inhibitory mechanism provides a several-fold preference 
of DNMT1 for hemimethylated DNA, but this is not 
sufficient to explain the faithfulness of in  vivo mainte-
nance methylation. A second mechanism that increases 
the preference of DNMT1 for hemimethylated DNA 
involves the interaction of the replication focus target-
ing sequence (RFTS) of DNMT1 with the multidomain 
protein UHRF1 (ubiquitin-like with PHD and ring finger 
domains 1), which contains an SRA domain that binds 
to hemimethylated CpG dinucleotides [36]. In the free 
protein, the RFTS of DNMT1 occludes access of DNA to 
the active site by impingement on the CXXC domain; it 
is proposed that the UHRF1/hemimethylated DNA com-
plex displaces the inhibitory RFTS domain of DNMT1 
in a handoff reaction to transfer hemimethylated DNA 
from UHRF1 to the active site of DNMT1. This proposal 
is consistent with the finding that UHRF1 is required for 
maintenance methylation in  vivo; null alleles of Uhrf1 
phenocopy null alleles of Dnmt1 in mice [36]. UHRF1 
has multiple additional functional domains (including a 
tandem tudor domain that has been reported to bind to 
methylated H3K9 and to regulate the fidelity of mainte-
nance methylation [37]), but mutation of UHRF1 so as to 
eliminate H3K9 binding had little effect on maintenance 
methylation in vivo [38].
DNMT1 also contains two bromo-adjacent homol-
ogy (BAH) domains that occur in a number of other 
proteins, where some have been shown to bind to spe-
cific modified histones (reviewed in [39]). The function 
of the BAH domains in DNMT1 is unknown, although 
they may increase the efficiency of maintenance meth-
ylation by interaction with unidentified histones or his-
tone modifications. While purified DNMT1 does have 
a modest intrinsic preference for hemimethylated DNA 
in vitro, it has recently become clear that multiple addi-
tional regulatory inputs, especially those mediated by the 
interaction with UHRF1, are required in  vivo to ensure 
stable maintenance methylation at ICR/DMRs and other 
sequences where DNA methylation is subject to stable 
somatic inheritance.
Pathogenic mutations in DNA methyltransferase 
genes
All three human genes that encode active DNA methyl-
transferases have been found to be mutated in specific 
human diseases, although gross methylation abnormali-
ties have been observed only in ICF syndrome type 1 
(immunodeficiency, centromere instability, facial anom-
alies; OMIM 602900), which is caused by homozygous 
loss-of-function mutations at DNMT3B ([43]; Fig.  4a). 
ICF syndrome type 1 patients present with a variable 
combined immunodeficiency that is usually fatal prior 
to adulthood, mild but stereotypical facial abnormalities, 
and severe instability of classical satellite DNA on chro-
mosomes 1, 9, and 16 that leads to gains and losses of 
chromosome arms to produce multiradiate or pinwheel 
chromosomes in phytohaemagglutinin (PHA)-stimu-
lated T cells. Classical satellite DNA is almost completely 
unmethylated in all cells of patients with this syndrome, 
but chromosome instability is apparent only in cer-
tain cell types. Variable losses of methylation in other 
regions of the genome have also been reported [44], but 
the methylation abnormalities responsible for the patho-
genesis of ICF syndrome cannot be specified with any 
confidence. While point mutations in DNMT3B in ICF 
syndrome type 1 can eliminate all enzyme activity [43], 
ICF patients homozygous for deletion or early truncation 
alleles have not been reported. Null alleles of Dnmt3B 
in mice are embryonic lethals [45], which suggests that 
DNMT3B protein, even if enzymatically inactive, is 
required for proper assembly and function of a complex 
that contains other factors.
Heterozygous somatic mutations in DNMT3A are 
present in ~15% of cases of acute myeloid leukemia 
(AML; OMIM 601626) [46] and in a smaller percent-
age of cases of myelodysplastic syndrome. Most muta-
tions affect a single codon: R882 (encoded by CGC). 
C  →  T mutations at a methylated CpG dinucleotide 
within this codon convert it to a cysteine codon (TGC) 
if the top strand is mutated and to a histidine codon 
(CAC) if the bottom strand is mutated (Fig. 4b). It is not 
known whether methylation abnormalities are involved 
in those AML cases that bear mutations in DNMT3A. 
Mutations in DNMT3A are uncommon in neoplastic 
conditions other than certain leukemias and myelodys-
plastic syndrome.
Tatton–Brown–Rahman syndrome (OMIM 602769) is 
an overgrowth syndrome that involves tall stature, char-
acteristic facial anomalies, and variable intellectual dis-
abilities. The original authors referred to this condition 
as DNMT3A overgrowth syndrome [47]. Patients are 
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Fig. 3 Structure and regulation of DNMT1. a Functional domains in DNMT1. A nuclear localization sequence (NLS) and replication focus targeting 
sequence (RFTS) are closest to the N-terminus. A CXXC domain binds selectively to unmethylated CpG dinucleotides; this binding event interposes 
an acidic autoinhibitory loop between the active site and unmethylated DNA to inhibit de novo methylation [30]. The bromo-adjacent homol-
ogy (BAH) domains 1 and 2 are of unknown function but are related in structure to BAH domains in other proteins that bind to specific modified 
histones (reviewed in [39]). A run of alternating lysine and glycine residues joins the multidomain N-terminal domain to the large C-terminal methyl-
transferase domain, which is related in sequence and structure to all other DNA (cytosine-5) methyltransferases (reviewed in [35]). Letters below the 
diagram indicate the position of N-terminal truncations in the crystal structures shown in b–e. b Superposition of the structures of active DNMT1 
[30] and M.HhaI, a bacterial restriction methyltransferase [40]. The methyltransferase domain of DNMT1 shows strong isostery with full-length 
M.HhaI. c Superposition of autoinhibited DNMT1 in complex with unmethylated DNA and active DNMT1 deleted for the CXXC and autoinhibitory 
loop domains in complex with hemimethylated DNA [41]. DNA can be seen to have accessed the catalytic pocket of DNMT1 in the active complex 
and to be very close to the S-adenosyl-l-homocysteine present in both complexes. d, e Impingement of the RFTS on the CXXC domain displaces 
the latter (curved arrow) into a conformation that inhibits binding of DNA [42]. It is proposed that the interaction of UHRF1 bound to hemimethyl-
ated DNA causes a retraction of the RFTS domain to allow access of hemimethylated DNA to the active site of DNMT1 [42]
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heterozygous for germ line mutations in DNMT3A dif-
ferent from those reported to occur somatically in AML 
(Fig.  4b). It is not known whether DNA methylation 
abnormalities are present in Tatton–Brown–Rahman 
syndrome; the early-onset overgrowth phenotype is 
not inconsistent with defects in imprinted gene expres-
sion. Although there are no methylation data on this 
point, there are strong phenotypic similarities among 
Fig. 4 Each of the three DNMT genes is mutated in specific and diverse human syndromes. a DNMT3B bears recessive loss-of-function mutations 
in ICF syndrome type 1. b DNMT3A is mutated in dominant DNMT3A overgrowth syndrome and in subset of cases of acute myeloid leukemia 
and myelodysplastic syndrome. While most AML/MDS mutations affect codon 882, mutations at other positions also occur. c The RFTS domain of 
DNMT1 is subject to many different dominant mutations in a variable adult-onset cerebellar ataxia, deafness, dementia, and narcolepsy syndrome. 
The RFTS mediates interactions with replication foci during S phase (d) and with UHRF1. The positions of the amino acid substitutions within the 
structure of DNMT1 are shown in e. Only a subset of reported disease-associated mutations are shown for any of the three genes
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Tatton–Brown–Rahman syndrome, Weaver syndrome 
(associated with heterozygous missense mutations in 
EZH2; OMIM 277590), and Sotos syndrome (usually 
associated with heterozygous loss-of-function muta-
tions in NSD1; OMIM 117550) and the imprinting disor-
der Beckwith–Wiedemann syndrome (OMIM 130650), 
which strengthens the possibility that all these syndromes 
involve disruption of normal imprinted gene expression 
(reviewed in [47]).
Multiple dominant germ line mutations clustered in a 
single small domain of DNMT1 cause a heterogeneous 
group of adult-onset neurological disorders that include 
ataxia, sensorineural deafness, narcolepsy, dementia, 
psychosis, and other neurological and psychiatric abnor-
malities (OMIM 126375 and 605712) that are collectively 
known as autosomal dominant DNMT1 complex disor-
der [48]. All the known causative mutations involve sin-
gle amino acid substitutions within the replication focus 
targeting sequence (RFTS; Fig.  4c), which mediates the 
interaction of DNMT1 and UHRF1 and the recruitment 
of DNMT1 into replication foci during S phase; in non-S 
phase cells, DNMT1 has a diffuse nucleoplasmic distri-
bution (Fig. 4d). The locations of the causative mutations 
within the structure of DNMT1 are shown in Fig. 4e.
That mutations in DNMT1 should cause adult-onset 
neurological defects without involvement of other tissues 
is unexpected; partial loss-of-function alleles of Dnmt1 in 
mice cause pervasive developmental delays and high rates 
of leukemia without obvious neurological abnormalities 
[49]. Furthermore, adult neurons are postmitotic and 
perform little or no maintenance methylation. DNMT1 
protein is nonetheless present at appreciable levels in 
neurons, and the mutated proteins show a tendency to 
form cytoplasmic aggregates when overexpressed in cul-
tured cells [48]. It is likely that the toxicity of these aggre-
gates (if they form in neurons of affected individuals), 
rather than an effect on DNA methylation, underlies the 
neuropathies caused by mutations in DNMT1. This inter-
pretation is consistent with the report of a lack of obvious 
phenotypes after conditional deletion of the Dnmt1 gene 
in postmitotic neurons of mice [50].
DNMT3L, which is expressed only in prospermato-
gonia and in growing oocytes, recruits DNMT3A and 
DNMT3B to nucleosomes that contain unmethylated 
H3K4 [51]. No disease-associated mutations in the 
DNMT3L gene have been reported in humans; based 
on mouse models, homozygous null alleles would be 
expected to produce non-syndromic azoospermia in 
males and maternal-effect embryonic lethality in the off-
spring of homozygous mutant females and normal males 
[11, 12].
The human biology of DNA methyltransferases illus-
trates the complex and enigmatic effects of disturbances 
of genomic methylation patterns on phenotype. The four 
human disorders firmly associated with mutations in 
DNA methyltransferase genes have largely non-overlap-
ping phenotypes: one is germ line, recessive, early onset 
and involves a usually severe combined immunodefi-
ciency (ICF syndrome type 1), one is germ line, domi-
nant, adult onset and progressive and affects the central 
nervous system (DNMT1 complex disorder), another is 
germ line, dominant, early onset and involves overgrowth 
and intellectual disabilities without pronounced neuro-
logical disturbance (Tatton–Brown–Rahman or domi-
nant DNMT3A overgrowth syndrome), and another is 
somatic, dominant and is involved in the etiology of lym-
phoid neoplasms (DNMT3A mutations at codon R882). 
Methylation abnormalities are likely to be involved in 
the causation of all the conditions. Given the vast num-
ber of methylation patterns that can exist on a single 
genome and the high likelihood that the DNA methyl-
transferase mutations will cause genome-wide meth-
ylation abnormalities, it might be extremely difficult to 
identify the specific methylation change that gives rise 
to a given biological effect in the DNA methyltransferase 
disorders. A recent report of characteristic methylation 
anomalies in DNMT3AR882H/+ or DNMT3AR882C/+ cases 
of AML that are not present in DNMT3A+/+ cases [52] 
highlights the issue: while the data strongly indicate that 
abnormal genomic methylation patterns are involved in 
the progression to AML, the methylation changes actu-
ally directly involved in leukemogenesis will be difficult 
to define.
Conclusions
Many of the accepted views of the form, function, and 
dynamics of mammalian genomic methylation patterns 
were first formulated in the 1980s, when there was little 
information as to the true organization of the genome. 
A reappraisal in view of modern information leads to 
the conclusion that the dynamic demethylation and 
remethylation that occurs in early development affect 
largely unannotated sequences and inactive transposons, 
while imprinting control regions and potentially active 
transposons largely escape demethylation, and nearly 
all CpG-rich promoters are not methylated in any cell 
type. Genomic methylation patterns at sequences where 
methylation status might affect phenotype are much 
more static than previously believed, while methylation 
changes at sequences that are evolving at close to the 
neutral rate are unlikely to have biological consequences.
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